Musculoskeletal adverse effects associated with inhaled levofloxacin in a patient with cystic fibrosis: A case report.

Respir MedJun 7, 2026 (epub)
Case ReportPulmonologyInfectious Diseases

Sayed Alwadaei, Nicki Allsup, Dejene Shiferaw

✦ AI-curated · Sources linked

Case in brief

A 26-year-old woman with cystic fibrosis experienced recurrent diffuse musculoskeletal pain linked to inhaled levofloxacin therapy. The pain occurred only during treatment cycles and resolved after discontinuation of the medication, with no recurrence noted since. This case suggests a potential adverse effect of inhaled levofloxacin that warrants further attention from clinicians.

Diagnostic / clinical pearl

Clinicians should be aware of the possibility of musculoskeletal pain as an adverse effect of inhaled levofloxacin in cystic fibrosis patients, despite its generally favorable safety profile.

Source

PubMed · PMID 42259475

Published in Respir Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pulmonology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.